Related Experiment Videos
When progression-free survival fails to inform: the need for event-level reporting in oligometastatic radiotherapy
Cole Friedes1, David Palma2, Nina N Sanford3
1Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Abstract:
Progression-free survival treats biologically and clinically distinct progression events equivalently, limiting its interpretability in oligometastatic radiotherapy trials. Across 21 randomized trials, event-level reporting was frequently absent, and none described how post-radiotherapy imaging was adjudicated within PFS. Pragmatic reporting standards could improve interpretation without requiring new endpoints or altered trial design.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...